Spots Global Cancer Trial Database for Imatinib in Dermatofibrosarcoma Protuberans (DFSP)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Imatinib in Dermatofibrosarcoma Protuberans (DFSP)
Official Title: Open-label Trial of Glivec® (Imatinib Mesylate) in Patients With Primary or Recurrent Dermatofibrosarcoma Protuberans
Study ID: NCT00122473
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to determine whether imatinib is effective in the treatment of primary and recurrent dermatofibrosarcoma protuberans (DFSP).
Detailed Description: This study is aimed to investigate the efficacy of imatinib (Glivec) in the treatment of primary and locally relapsed dermatofibrosarcoma protuberans (DFSP). DFSP is a cutaneous neoplasm well known for its overexpression of the platelet-derived growth factor (PDGF). Herein, imatinib provides a systemic treatment option that offers the possibility of a reduction of the wide surgical margins used today in surgery of primary DFSP, or even of a complete avoidance of surgical treatment in this disease. Since imatinib exerts its function via interference with protein tyrosine kinase activities, it inhibits the platelet-derived growth factor receptor (PDGF-R) signaling cascade that plays a crucial role in the pathogenesis and tumor growth of DFSP. Since imatinib has been shown to shrink metastatic lesions of DFSP, there is a strong rationale to expect that it also decreases cell proliferation and tumor growth in primary DFSP.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Skin Cancer Unit, German Cancer Research Center and Department of Dermatology, University Hospital of Mannheim, Mannheim, Baden-Württemberg, Germany
Department of Dermatology, ElbeKliniken - Klinikum Buxtehude, Buxtehude, Niedersachsen, Germany
Department of Dermatology, The Saarland University Hospital, Homburg/Saar, Saarland, Germany
Department of Dermatology, Martin-Luther-University Halle-Wittenberg, Halle/Saale, Sachsen-Anhalt, Germany
Contact Details
Name: Selma Ugurel, MD
Affiliation: Skin Cancer Unit, German Cancer Research Center Heidelberg and Department of Dermatology, University Hospital of Mannheim, Mannheim, Germany
Role: PRINCIPAL_INVESTIGATOR
Name: Dirk Schadendorf, MD
Affiliation: Skin Cancer Unit, German Cancer Research Center Heidelberg and Department of Dermatology, University Hospital of Mannheim, Mannheim, Germany
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
